Bryce A. Kiberd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bryce A. Kiberd has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Catherine M. Clase
McMaster University, Hamilton, Ontario, Canada
2 shared publicationsTammy Keough-Ryan
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
2 shared publicationsRoman Panek
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
1 shared publication
Latest Publications
- Open Access
- 1 November 2003
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (11) , 1393-1399
Cardiovascular Disease Reduction in the Outpatient Kidney Transplant Clinic
- 1 November 2003
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (11) , 1393-1399
Open AccessCardiovascular Disease Reduction in the Outpatient Kidney Transplant Clinic
- Open Access
- 1 May 2003
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (5) , 619-625
Screening for Prostate, Breast and Colorectal Cancer in Renal Transplant Recipients
American Society of Transplantation guidelines recommend screening renal transplant recipients for breast, colorectal and prostate cancer. However there is a lack of evidence to support this practice. Computer simulation modeling was used to estimate the years of life lost as a result of these cancers in 50-year-old renal transplant recipients and subjects in the general population. Renal transplant recipients lost fewer years of life to cancer than people in the general population largely because of reduced life expectancy. In nondiabetic transplant recipients, loss of life as a result of these cancers was comparable with that in the general population only under assumptions of increased cancer incidence and cancer-specific mortality risks. Even with two-fold higher cancer incidence and disease-specific mortality risks, diabetic transplant recipients lost considerably fewer life years to cancer than those in the general population. Recommended cancer screening for the general population may not yield the expected benefits in the average renal transplant recipient but the benefits will be considerably higher than for patients on dialysis. Transplanted patients at above-average cancer risk in good health may achieve the benefits of screening that are seen in the general population.
- 1 May 2003
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (5) , 619-625
Open AccessScreening for Prostate, Breast and Colorectal Cancer in Renal Transplant Recipients
American Society of Transplantation guidelines recommend screening renal transplant recipients for breast, colorectal and prostate cancer. However there is a lack of evidence to support this practice. Computer simulation modeling was used to estimate the years of life lost as a result of these cancers in 50-year-old renal transplant recipients and subjects in the general population. Renal transplant recipients lost fewer years of life to cancer than people in the general population largely because of reduced life expectancy. In nondiabetic transplant recipients, loss of life as a result of these cancers was comparable with that in the general population only under assumptions of increased cancer incidence and cancer-specific mortality risks. Even with two-fold higher cancer incidence and disease-specific mortality risks, diabetic transplant recipients lost considerably fewer life years to cancer than those in the general population. Recommended cancer screening for the general population may not yield the expected benefits in the average renal transplant recipient but the benefits will be considerably higher than for patients on dialysis. Transplanted patients at above-average cancer risk in good health may achieve the benefits of screening that are seen in the general population.
- 1 June 2002
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 13 (6) , 1635-1644
Cumulative Risk for Developing End-Stage Renal Disease in the US Population
The individual risk of developing end-stage renal disease (ESRD) and its overall impact on life expectancy is not known. This study’s objectives were to determine the effect of ESRD on life expectancy for a cohort of 20-yr-olds and to compare this impact to that of several cancers for which population-based screening programs exist. A computer simulation, stratified by race (white, black) and by gender was used to calculate cumulative lifetime risk of ESRD, life-years lost to ESRD, and cumulative Medicare payments for ESRD. Similar calculations were made for breast, prostate, and colorectal cancer. The cumulative lifetime risk of ESRD for a 20-yr-old black woman is 7.8%. Equivalent risks for black men are 7.3%, white men 2.5%, and white women 1.8%. Lost years of life attributable to ESRD are 1.09, 1.10, 0.40, and 0.32 yr for black women, black men, white men, and white women, respectively. In blacks, ESRD is responsible for nearly as much loss of life-years as breast cancer in women and more loss of life-years than colorectal or prostate cancer in men. In addition, treatment costs for ESRD in this population are many-fold more expensive than cumulative treatment costs of these cancers. Exploring new screening and treatment strategies may be warranted to prevent ESRD, particularly in the US black population.
- 1 June 2002
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 13 (6) , 1635-1644
Cumulative Risk for Developing End-Stage Renal Disease in the US Population
The individual risk of developing end-stage renal disease (ESRD) and its overall impact on life expectancy is not known. This study’s objectives were to determine the effect of ESRD on life expectancy for a cohort of 20-yr-olds and to compare this impact to that of several cancers for which population-based screening programs exist. A computer simulation, stratified by race (white, black) and by gender was used to calculate cumulative lifetime risk of ESRD, life-years lost to ESRD, and cumulative Medicare payments for ESRD. Similar calculations were made for breast, prostate, and colorectal cancer. The cumulative lifetime risk of ESRD for a 20-yr-old black woman is 7.8%. Equivalent risks for black men are 7.3%, white men 2.5%, and white women 1.8%. Lost years of life attributable to ESRD are 1.09, 1.10, 0.40, and 0.32 yr for black women, black men, white men, and white women, respectively. In blacks, ESRD is responsible for nearly as much loss of life-years as breast cancer in women and more loss of life-years than colorectal or prostate cancer in men. In addition, treatment costs for ESRD in this population are many-fold more expensive than cumulative treatment costs of these cancers. Exploring new screening and treatment strategies may be warranted to prevent ESRD, particularly in the US black population.
- 1 June 2002
- Vol. 54 (2) , 51-63
Cardiovascular risk reduction in renal transplantation. Strategies for success.
One of the aims of transplantation is to restore the potential for a full life to individuals with ESRD. To obtain this strategies that allow better and longer allograft function and a reduction in adverse events that lead to premature death are required. To this end, the recommendations below showed reduce cardiovascular disease and help present and future transplant recipients live a full life. Focusing on traditional risk factors (hypertension, hyperlipidemia, discontinuation of smoking, and prevention and treatment of diabetes mellitus) in patients at risk and striving for the recommended targets will have the greatest clinical benefit. These strategies should begin in the pre-dialysis and dialysis phases in order to reduce the cumulative burden of disease. Failing this, early and hopefully pre-emptive transplantation should be the goal.
- 1 June 2002
- Vol. 54 (2) , 51-63
Cardiovascular risk reduction in renal transplantation. Strategies for success.
One of the aims of transplantation is to restore the potential for a full life to individuals with ESRD. To obtain this strategies that allow better and longer allograft function and a reduction in adverse events that lead to premature death are required. To this end, the recommendations below showed reduce cardiovascular disease and help present and future transplant recipients live a full life. Focusing on traditional risk factors (hypertension, hyperlipidemia, discontinuation of smoking, and prevention and treatment of diabetes mellitus) in patients at risk and striving for the recommended targets will have the greatest clinical benefit. These strategies should begin in the pre-dialysis and dialysis phases in order to reduce the cumulative burden of disease. Failing this, early and hopefully pre-emptive transplantation should be the goal.